natgillin/translations-raw huggingface dataset:
at least a subset of said locking tumblers comprising a body part and an integral key sensing part for engagement with an associated key, said body part being mounted in an associated chamber in said key plug for elevational movement therein along a tumbler axis in parallel with an axis of said associated chamber, and keys of the kind comprising: 
barem podskup navedenih čepića za zaključavanje sadrži dio kućišta (206a) 1 integralni dio za raspoznavanje ključa (206b) za međudjelovanje sa odgovarajućim ključem (100), te je navedeni dio kućišta postavljen u odgovarajuću komoru (208) navedenog uloška za ključ radi vertikalnog pomicanja uzduž osi čepića paralelno s osi navedene odgovarajuće komore,
The compound of any of claims 1 to 18 or the pharmaceutical composition of claim 19 for use in treatment of Wilson's disease, spinocerebellar ataxia, prion disease, Parkinson's disease, Huntington's disease, amytrophic lateral sclerosis, amyloidosis, Alzheimer's disease, Alexander's disease, alcoholic liver disease, cystic fibrosis, Pick's Disease, spinal muscular dystrophy or Lewy body dementia. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 18 ili farmaceutski pripravak prema patentnom zahtjevu 19 za uporabu u liječenju Wilson-ove bolesti, spinocerebelarne ataksije, prionske bolesti, Parkinson-ove bolesti, Huntington-ove bolesti, amiotrofne lateralne skleroze, amiloidoze, Alzheimer-ove bolesti, Alexander-ove bolesti, alkoholne bolesti jetre, cistične fibroze, Pick-ove bolesti, spinalne muskularne atrofije ili demencije sa Lewy-evim tijelima.
In order to highlight these warnings the LED diode 112 is green, the LED diode 114 red. 
HR P20060438 T3 dioda 112 je zelena, a LED dioda 114 crvena.
A medicinal cream as claimed in claims 1 and 3 further comprising a buffering agent which is selected from a group comprising Di Sodium Hydrogen Ortho Phosphate, Sodium Hydrogen Ortho Phosphate and the like, or any combination thereof and added in an amount from about 0.001 % (w/w) to 1.00% (w/w). 
Medicinska krema prema patentnim zahtjevima 1 13, naznačena time, da nadalje sadrži puferski agens koji se odabire iz skupine koja sadrži dinatrijev hidrogenortofosfat, natrijev hidrogenortofosfat i slične, ili bilo koju njihovu kombinaciju i dodaje u količini od oko 0,001% (tež.) do 1,00% (tež.).
It is believed that control of the lozenge pH, and in particular the use of phosphate buffers is advantageous in providing an improved taste or “mouth feel”. 
Vjeruje se da je kontrola pH tablete, i posebno uporaba fosfatnih pufera korisna u osiguravanju poboljšanog ukusa ili "osjećaja u ustima".
WO 00/08938 A1 (now EP 1 104 241 B1, Bayer CropScience) describes the use of herbicide combinations for fighting weeds in herbicide resistant oilseed rape. 
WO 00/08938 A1 (sada EP 1 104 241 BI, Bayer CropScience) opisuje primjenu herbicidnih kombinacija za borbu protiv korova kod uljane repice koja je otporna na herbicid.
and R2 independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, mercapto, cyano, nitro, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylthio, C1-C6alkylcarbonyloxy, C1-C6alkylsulfonyloxy, C1-C6heteroalkylcarbonyloxy, C5-C6heterocyclylcarbonyloxy, C1-C6heteroalkoxy, wherein heteroalkyl, heteroalkoxy groups or heterocyclyl comprise 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, in which substituents the alkyl moieties are unsubstituted or further substituted; 
R1! i R2, međusobno neovisno, predstavljaju vodik ili supstituent kojeg se bira između hidroksi, halogena, mercapto, cijano, nitro, C;-CÂ«alkil, C,-Cgalkoksi, C,-C4alkiltio, Cy-Csalkilkarboniloksi, C;-Cgalkilsulfoniloksi, C,- CÂ«heteroalkilkarboniloksi, Cs-Cgheterociklilkarboniloksi, C;,-Cgheteroalkoksi, gdje heteroalkil, heteroalkoksi skupine ili heterociklil sadrže 1, 2 ili 3 heteroatoma, koje se bira između dušika, kisika i sumpora, gdje su u navedenim supstituentima alkilni ostaci nesupstituirani ili daljnje supstituirani;
The immunogenic composition of claim 1 wherein said N. meningitidis capsular saccharide is conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT, protein D, OMPC and pneumolysin. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna bakterijska saharida su konjugirani s proteinskim nosačem kojeg se bira iz skupine koju čine TT, DT, CRM197, C fragment proteina TT, protein D, OMPC i pneumolizin.
The method of any one of claims 1-10, wherein the deleted endogenous nucleic acid sequence ranges from about 5 kb to about 10 kb, from about 10 kb to about 20 kb, from about 20 kb to about 40 kb, from about 40 kb to about 60 kb, from about 60 kb to about 80 kb, from about 80 kb to about 100 kb, from about 100 kb to about 150 kb, or from about 150 kb to about 200 kb, from about 200 kb to about 300 kb, from about 300 kb to about 400 kb, from about 400 kb to about 500 kb, from about 500 kb to about 1 Mb, from about 1 Mb to about 1.5 Mb, from about 1.5 Mb to about 2 Mb, from about 2 Mb to about 2.5 Mb, or from about 2.5 Mb to about 3 Mb. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1-10, naznačen time, da se izbrisana endogena sekvenca nukleinske kiseline od oko 5 kb do oko 10 kb, od oko 10 kb do oko 20 kb, od oko 20 kb do oko 40 kb, od oko 40 kb do oko 60 kb, od oko 60 kb do oko 80 kb, od oko 80 kb do oko 100 kb, od oko 100 kb do oko 150 kb, ili od oko150 kb do oko 200 kb, od oko 200 kb do oko 300 kb, od oko 300 kb do oko 400 kb,od oko 400 kb do oko 500 kb, od oko 500 kb do oko 1 Mb, od oko 1 Mb do oko 1.5 Mb, od oko 1.5 Mb do oko 2 Mb, od oko 2 Mb do oko 2.5 Mb, ili od oko 2.5 Mb do oko 3 Mb.
This was concentrated to an oil, dissolved in 20 mL ethanol and treated with 10 mL 6N HCl and warmed at 60° C. for 2 h. 
Ovo je koncentrirano do ulja, otopljeno u 20 mL etanola i tretirano sa 10 mL 6N HC1 1 zagrijavano na 60C 2 sata.
A pharmaceutical composition comprising the antibody of any one of claims 1-9 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo sukladno bilo kojem od patentnih zahtjeva 1-9 i farmaceutski prihvatljiv nosač.
thiomorpholinyl, piperidinyl, pyrrolidinyl, and morpholinyl; wherein said piperidinyl, and pyrrolidinyl are optionally substituted with CF3, CH2F, CH2CH2F, C(1-2)alkyl, —CN, OH, or CH2OH, and up to three additional substituents selected from the group consisting of CH3, and F; 
o LAI domarfolii, piperidinil, pirolidinil, i morfolinil; pri čemu su navedeni piperidinil | i pirolidinil proizvoljno supstituirani s CF3, CH>F, CHoCHbF, Ca-alkil, -CN, OH, ili CH2OH, 1 do tri dodatna supstituenta odabrana iz skupine koju čine CH-, i F;
The combination for use according to any one of claims 1 to 14, wherein the following are orally administered: about 300 mg. of netupitant as a free base on day one; about 0.56 mg. of palonosetron hydrochloride (corresponding to about 0.5 mg of palonosetron as a free base) on day one; 
Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačena time što se slijedeći primjenjuju oralno: a) oko 300 mg netupitanta kao slobodna baza na dan jedan; b) oko 0.56 mg palonosetron hidroklorida (odgovara oko 0.5 mg palonosetrona kao slobodna baza) na dan jedan;
4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 
4,759,923, kvaterni amini, poli(dialildimetilamonijev klorid) i ioni kao što su oni izneseni u U.S. Patentnom br.
The process of claim 5, wherein, in the mixed solution of an organic acid and an inorganic acid used in said step b), the mass percentage concentration of the inorganic acid in the mixed solution is 0.1% to 15%. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što je, u miješanoj otopini organske kiseline i anorganske kiseline upotrijebljenoj u navedenom koraku 2), masena postotna koncentracija anorganske kiseline u miješanoj otopini 0,1%-15%.
The process or composition of any preceding claim, wherein the composition comprises SDS/IL-2 microaggregates with a hydrodynamic diameter between 11 nm and 13 nm. 
Sastav prema bilo kojem od patentnih zahtjeva 10-13, naznačen time, da sastav sadrži SDS/IL-2 mikroagregate s hidrodinamičkim promjerom između 11 nm i 13 nm.
A method of manufacturing a hop containing beverage that is resistant to light induced flavour changes, said method comprising introducing into said beverage a light stabilising composition containing at least 0.5% by weight of dry matter, of pyrazine derivatives according to formula (I): 
Pripravak koji se može prikladno upotrijebiti kao aditiv u pićima i prehrambenim proizvodima, naznačen time, što: i. > sadržava najmanje 0,5%, poželjno najmanje 1,0%, po masi suhe tvari, derivata pirazina prema formuli (T):
According to another preferred embodiment of the inventive process, the surface reacted calcium carbonate obtained by the inventive process has a BET specific surface area, measured according to the measurement method provided in the examples section hereafter, of at least 20 m2/g, preferably of at least 30 m2/g, more preferably of at least 40 m2/g, even more preferably of at least 50 m2/g, still more preferably of at least 60 m2/g, yet more preferably of at least 70 m2/g and most preferably of at least 80 m2/g. 
Postupak prema bilo kojem od zahtjeva 1 do 18, naznačen time da površinski reaktivni kalcijev karbonat koji je dobiven sa postupkom ima specifičnu površinu prema BET-u od barem 20 m/g, poželjno barem 30 m"/g, još poželjnije barem 40 m//g, još više poželjno barem 50 m//g, još više poželjno barem 60 m'/g, još više poželjno barem 70 m'/g, te najpoželjnije barem 80 m"/g. .
neuroblastoma; or 
(iv) neuroblastom; ili
conversion of F*, particularly under catalytic esterification conditions, to create compound 5* (having a second benzyl protection group at the nitrogen atom instead of the phenyl fluorenyl group in compound 5); 
F*; E (e) prevođenje spoja F ili spoja F*, naročito pod uvjetima katalitičke esterifikacije, kako bi se dobio spoj 5 ili 15
upon infrared analysis (FT-IR), bands typical of the 1,4- cis and 1,2 sequences centered at 737 cm-1 and at 911 cm-1, respectively; 
kod infracrvene analize (FT-IR), pojaseve tipične za nizove 1,4-cis 1 1,2, centrirane na 737 cm"! odnosno na911 cm!;
Docusate salts, e.g., dioctylsulfosuccinate or related compounds, such as di-[2-ethylhexyl]-succinate. 
10) Dokusat soli, na primjer dioktilsulfosukcinat ili slične spojeve kao što je di-[2-etilheksil]-sukcinat.
the isolated nucleic acid molecule according to claim 4; or (b) 
(a) izoliranu molekulu nukleinske kiseline prema patentnom zahtjevu 4; ili (b)
The method of claim 16 or 17 wherein said air plenum (48) is adjustable carried on said section box (20) and which also includes the step of adjusting the position of the air plenum relative to the section box. 
Postupak u skladu s patentnim zahtjevom 16 ili 17, naznačen time što je navedeni razdjelnik za zrak (48) postavljen na navedeno profilno kućište (20) na takav način da se može podešavati i što osim toga obuhvaća i fazu koja omogućava namještanje položaja razdjelnika za zrak u odnosu na profilno kučište.
The gel presented on FIG. 7 containing different fractions of the chromatographic separation, the reference material and molecular weight markers is stained with Coomassie blue. 
Gel prikazan na Slici 7, koji sadrži različite frakcije dobivene kromatografskim razdvajanjem, referentni materijal i markere za molekularnu težinu, obojan je sa Coomassie blue.
The hybrid fuel supply system according to claim 1, further comprising a fuel pump provided in the LNG cargo tank and configured to supply the LNG stored in the LNG cargo tank to the high pressure pump. 
Sustav za slanje hibridnog goriva u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što dodatno uključuje crpku za gorivo (320,2), smještenu u spremniku za LNG kao teret (CT,1) i konfiguriranu za slanje LNG-a spremljenog u spremniku za LNG kao teret (CT,1) u visokotlačnu crpku (300,120).
The pharmaceutical composition of the above (30.), wherein the aqueous buffer provides a pH to the composition of about 6. 
Farmaceutska kompozicija patentnog zahtjeva 3 ili patentnog zahtjeva 4, gdje farmaceutska kompozicija ima pH od oko 4 do oko 6.
A method for treating a muscle-wasting disease or a metabolic disorder in a subject, comprising administering an effective amount of the protein of claim 1 to the subject. 
u liječenju bolesti koja dovodi do atrofije mišića ili metaboličkog poremećaja kod subjekta kojem je potrebna takva terapija; ili
The calcium carbonate of said carbonate-comprising material may be a precipitated calcium carbonate (PCC), a natural ground calcium carbonate (NGCC), a surface-reacted calcium carbonate (SRCC), or a mixture thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni materijal koji sadrži kalcijev karbonat istaloženi kalcijev karbonat (PCC), prirodna ruda kalcijevog karbonata (NGCC), površinski- izreagirani kalcijev karbonat (SRCC) ili njihova smjesa.
The antibody of claim 15, wherein the antibody comprises the variable heavy chain of SEQ ID NO: 31 and the variable light chain of SEQ ID NO: 32. 
antitijelom koje ima teški lanac kao što je prikazano u SEK ID BR: 31 i laki lanac kao što je prikazano u SEK ID BR: 32 i/ili
A preferred embodiment of the present invention is a combination of an M3 antagonist of the invention with a LABA selected from formoterol, salmeterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-149. 
Poželjno utjelovljenje predmetnog izuma je kombinacija M3 antagonista sukladno predmetnom izumu s kortikosteroidom odabranim između sljedećeg: budesonid, beklometazon dipropionat, mometazon furoat, ciklesonid i flutikazon propionat.
preparing a semi-manufactured component of an upper for a shoe, such that the semi-manufactured component is completely open to be spread out on a flat surface; 
- < priprave poluproizvedenog dijela gornjišta (12) za cipelu koje se može rasprostrijeti na ravnoj površini ili na dvije suprotne površine
A compound of formula (I) or a physiologically acceptable solvate thereof as defined in claim 13 for use in the treatment of patients with allergic dermatitis. 
Spoj formule (I), ili njegov fiziološki prihvatljiv solvat, u skladu s patentnim zahtjevom 13, naznačen time što je namijenjen upotrebi u liječenju pacijenata s alergijskim dermatitisom.
a heavy chain variable domain comprising a CDR1 region that comprises amino acids 31-35 of SEQ ID NO: 3, a CDR2 region that comprises amino acids 50-66 of SEQ ID NO: 3, and a CDR3 region that comprises amino acids 99-106 of SEQ ID NO: 3; and a light chain variable domain comprising a CDR1 region that comprises amino acids 24-38 of any one of SEQ ID NOs: 4, 11, or 12, a CDR2 region that comprises amino acids 54-60 of any one of SEQ ID NOs: 4, 11, or 12, and a CDR3 region that comprises amino acids 93-101 of any one of SEQ ID NOs: 4, 11 or 12; 
varijabilnu domenu teškog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 31-35 iz SEQ ID NO:3, CDR2 regiju koja sadrži aminokiseline 50-66 iz SEQ ID NO:3 i CDR3 regiju koja sadrži aminokiseline 99-106 iz SEQ ID NO:3; i varijabilnu domenu lakog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 24-38 iz bilo kojeg od SEQ ID NO: 4, 11 ili 12, CDR2 regiju koja sadrži aminokiseline 54-60 iz bilo kojeg od SEQ ID NO: 4, 11 ili 12 i CDR3 regiju koja sadrži aminokiseline 93-101 iz bilo kojeg odSEQ ID NO: 4, 11 ili 12;
In this way, the “metastability” of the first phase arises because the first phase is only “stable” as long as the chemical constituent is adsorbed thereto. 
Na taj način je "metastabilnost" prve faze povećana jer je prva faza "stabilna" dok se kemijski konstituent ne adsorbira.
selecting at least two amino acid positions within the VH region for mutation; and 
(A) odabiranje najmanje tri aminokiselinske pozicije unutar Vr-područja za mutaciju; 1
In Table 2 the weight loss (as % w/w of the total mixture) after subtraction of the loss attributable to the solvent is presented: 
U tablici 2 prikazan je gubitak mase (kao % masa/masa od ukupne smjese) nakon oduzimanja gubitka koji se može pripisati otapalu.
As stated above, the feed rate of the whole process from continuous casting to the last rolling stand is increasing step by step and corresponds to the respective thickness reduction required by the features, especially thickness and quality, of the desired end product. 
Kako je gore navedeno, brzina punjenja cijelog postupka od kontinuiranog lijevanja sve do zadnjeg valjačkog stana, povećava se korak po korak i odgovara smanjenju debljine koje je potrebno za postizanje osobina željenog završnog proizvoda, posebno debljine i kvalitete.
applying said film under tension around said bale, in direct contact with the compressed bulk material; and 
(c) nanošenje te napete folije oko bale, u izravnom doticaju s komprimiranim rasutim (bulk) materijalom; i
rearing the infected larvae or cultivating the cells until death by polyhedrosis; 
uzgojem inficiranih ličinki ili uzgoj stanica do smrti od poliedroze;
The coating composition according to any one of the preceding claims, wherein the polysiloxane-based binder system comprises (i) a binder and (ii) a cross-linking agent, wherein the binder (i) constitutes 20-90 % by dry weight of the coating composition, and is a curable diorganopolysiloxane represented by general formula (1): wherein 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da vezivni sustav na bazi polisiloksana sadrži (i), vezivo te (ii) sredstvo za poprečno povezivanje, pri čemu vezivo (1) čini 20-90% suhe mase smjese za premaz, te je diorganopolisiloksan koji se upotrebljava u liječenju i koji je predstavljen općom formulom (1):
The mixture was allowed to warm to room temperature and kept for three days at this temperature. 
Smjesa se pusti da se zagrije na sobnu temperaturu i održava se tri dana na ovoj temperaturi.
iii) at least 70 wt. % of the cellulosic biomass is converted to the unenriched renewable fuel oil; and 
Postupak prema jednom od prethodnih zahtjeva, naznačen time što je obnovljivo ulje goriva pomiješano s etanolom.
optionally followed by a Wittig reaction to generate the compound of Formula L, wherein R23 is selected from the group consisting of: —CH3 and —CH2CH3. 
3 Opcijski nakon toga slijedi Wittig reakcija da se dobije spoj od Formule L, naznačeno time, da je R23 odabran iz skupine koja sadrži i
Figure 4 shows a sheet metal strip on termination of the incision stage, 
prikazuje limenu metalnu traku na završetku faze urezivanja, slika 5
The ophthalmic device of any one of claims 1 to 10 comprising PRG4 at a concentration of 100-300 µg/mL. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 50-500 ug/mL.
a light chain variable region sequence encoded by a nucleotide sequence having at least 95% identity to any of the nucleotide sequences selected from the group consisting of SEQ ID NOS:136-138; and 
sekvenca varijabilnog predjela lakog lanca kodirana nukleotidnom sekvencom koja ima najmanje 95% identičnosti sa bilo kojom od nukleotidnih sekvenci izabranih iz grupe koja se sastoji od SEK ID BR: 136-138; i
One particularly preferred compound is 3′-[4-(1-Ethyl-5-methyl-1H-pyrazol-4-ylmethyl)-piperazin-1-yl]-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-4-ol or a pharmaceutically acceptable salt thereof, as for example the compound of Example 1. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3 '-[4-(1-etil-5-metil-177-pirazol-4-ilmetil)piperazin-1- il]-3,4,5,6-tetrahidro-27-1,2 'bipiridinil-4-ol, ili njegova farmaceutski prihvatljiva sol.
The isolated cell or tissue of claim 7 or 8, wherein the cell or tissue does not express a rodent SIRPa protein. 
Izolirana stanica ili tkivo u skladu s patentnim zahtjevom 6 ili 7, naznačeni time što stanica ili tkivo ne eksprimira glodavački protein SIRPa.
Weighing Anchor The user places the control levers in their neutral positions, and activates the system as described above. 
Podizanje sidra Korisnik postavlja upravljačke kontrole u njihov neutralni položaj, te aktivira sustav na način kao što je gore opisano.
R and R' are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; 
-12 alkil, C3-20 heterociklil i C5-20 aril, te opcijski zajedno u vezi sa skupinom NRR’, R i R’ zajedno s dušikovim atomom na kojega su priključeni, tvore opcijski supstituiran
The heterotrimeric fusion protein of any one of claims 1-10 for use in a method of treating a condition related to increased expression of TGFB, said use comprising administering an effective amount of the fusion protein to a subject in need thereof. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u postupku liječenja stanja povezanog s pojačanom ekspresijom TGFB, koja se sastoji u primjeni djelotvorne količine fuzijskog proteina na subjektu kojem je to potrebno.
A nitrogen scavenging drug for use in a method of treating hepatic encephalopathy (HE) in a subject, wherein the method comprises: 
Gliceril tri-[4-fenilbutirat] (HPN-100) za uporabu u postupku liječenja jetrene encefalopatije (HE) kod subjekta, naznačen time da postupak obuhvaća:
As illustrated above in the second reaction step of the alternative process of forming 7,9 acetal linked analogs of 9, 10-aa OH taxanes, the C7,C10 di-CBZ 10-deacetylbaccatin III of Formula 35 was coupled with a sidechain of Formula 36 to form Formula 37. 
Kao što je gore prikazano u drugom koraku reakcije alternativnog postupka formiranja 7,9 acetalno povezanih analoga 9,10-aa OH taksana, C7, C10 di-CBZ 10-deacetilbakatin III formule 35 je bio spojen s bočnim lancem formule 36 da bi se formirala formula 37.
alternatively, R12 and R13, together with the carbon atoms to which they are attached, combine to form a 5 to 6-membered carbocyclic ring or a 5 to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms; 
alternativno, R12 i R13, zajedno sa atomima ugljika za koje su vezani, kombiniraju se tako da formiraju 5- do 6-člani karbociklični prsten ili 5- do 6-člani zasićeni heterociklični prsten koji sadrži: atome ugljika i 1-2 atoma kisika;
The monolithic radiant panel as claimed in claim 1, wherein at least one of at least one of the two co-planar fin portions and the tubular portion is attached with the surface of the indoor area using an insulating material. 
Sustav s monolitnim radijativnim panelom u skladu s patentnim zahtjevom 1, naznačen time što je najmanje jedan od: najmanje jedan od dva koplanarna krilna dijela (104, 106), i cijevni dio (102) spojen s površinom zatvorenog prostora izolacijskim materijalom.
The reconstituted solution will be diluted depending on the concentration in the reconstituted solution and the desired concentration in the diluted solution. 
Rekonstruirana otopina će biti razrijeđena ovisno od koncentracije u rekonstruiranoj otopini i željene koncentracije u razrijeđenoj otopini.
In a related aspect, the invention contemplates a method for enhancing growth rate of cells in cell culture comprising culturing cells in culture media comprising an amount of alkyl-amine-n-oxide (AANOx) sufficient to improve the growth rate of the cells in culture. 
Postupak poboljšavanja stope rasta stanica u kulturi stanica koja sadrži uzgajane stanice u mediju za uzgoj u kulturi koja sadrži količinu alkil-amin-N-oksida (AANOx) dovoljna za poboljšavanje stope rasta stanica u kulturi, naznačen time što se količina AANOx kreće između 4 i 80 ppb, te